Literature DB >> 12210083

Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.

Benoît Terris1, Sylvie Dubois, Marie-Pierre Buisine, Alain Sauvanet, Philippe Ruszniewski, Jean-Pierre Aubert, Nicole Porchet, Anne Couvelard, Claude Degott, Jean-Francois Fléjou.   

Abstract

Intraductal papillary-mucinous tumours (IPMTs) of the pancreas are heterogeneous proliferations characterized by a malignant potential. The molecular mechanisms underlying the tumourigenesis process are not well understood. Recently, it has been shown that IPMTs secreting the mucin antigen MUC2 have a better prognosis, but the complete pattern of MUC gene expression has not yet been established. The aims of this study were to evaluate the mucin gene expression in 57 IPMTs and eight related lesions surgically resected and to relate MUC gene expression to the histological diagnosis. In situ hybridization (ISH) was performed in 28 cases with probes specific for the MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6, and MUC7 genes. An immunohistochemical analysis was carried in all 65 cases and in 90 conventional ductal adenocarcinomas of the pancreas using MUC1, MUC2, and MUC5AC antibodies. IPMTs of adenoma (dysplasia) type exhibited high expression of MUC2 (93%), MUC5AC (97%), and, to a lesser extent, of MUC4 (71%), all of which were also observed in colloid carcinomas associated with IPMTs. In contrast, IPMTs with simple hyperplasia, intraductal oncocytic papillary neoplasms, and pyloric glandular adenomas exhibited little or no expression of MUC2. The mucin expression profile supports the existence of two types of invasive tumour associated with IPMTs: a colloid and an ordinary form. The latter shows a pattern similar to the conventional ductal adenocarcinomas with a loss of MUC2 and a gain of MUC1 and has a greater tendency to metastasize. In conclusion, the altered expression of mucin, characteristic of IPMT of adenoma type and of colloid carcinomas, may contribute to the better clinical outcome of these neoplasms, compared to conventional pancreatic ductal adenocarcinomas. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210083     DOI: 10.1002/path.1146

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  38 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Intraductal papillary mucinous neoplasm (IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: a case of high-grade transformation of the gastric-type IPMN.

Authors:  Shinichi Ban; Yoshihisa Naitoh; Fumihiro Ogawa; Yoshihiko Shimizu; Michio Shimizu; Akihiro Yasumoto; Isamu Koyama
Journal:  Virchows Arch       Date:  2006-04-26       Impact factor: 4.064

3.  Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.

Authors:  Jin Hee Lee; Kyu Taek Lee; Jongwook Park; Sun Youn Bae; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

4.  Multicentric invasive carcinomas derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas: report of a case.

Authors:  Yoshihisa Naitoh; Shinichi Ban; Chouji Tsuchiya; Yoshiaki Sugiura; Michio Shimizu
Journal:  Virchows Arch       Date:  2007-02-28       Impact factor: 4.064

5.  Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma.

Authors:  Siliang Wang; Xiaodong Chen; Meiyue Tang
Journal:  Tumour Biol       Date:  2014-06-11

6.  Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases.

Authors:  Olca Basturk; Volkan Adsay; Gokce Askan; Deepti Dhall; Giuseppe Zamboni; Michio Shimizu; Karina Cymes; Fatima Carneiro; Serdar Balci; Carlie Sigel; Michelle D Reid; Irene Esposito; Helena Baldaia; Peter Allen; Günter Klöppel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2017-03       Impact factor: 6.394

7.  Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia.

Authors:  Terry K Morgan; Karin Hardiman; Christopher L Corless; Sandra L White; Robert Bonnah; Henry Van de Vrugt; Brett C Sheppard; Markus Grompe; Ediz F Cosar; Philip R Streeter
Journal:  Cancer Cytopathol       Date:  2012-07-18       Impact factor: 5.284

8.  Precursor lesions of pancreatic cancer.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Masamichi Goto
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

Review 9.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 10.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.